Nephrocare Health Services Ltd
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]
- Market Cap ₹ 5,138 Cr.
- Current Price ₹ 512
- High / Low ₹ 518 / 445
- Stock P/E 77.3
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 14.1 %
- ROE 13.4 %
- Face Value ₹ 2.00
Pros
- Company's working capital requirements have reduced from 33.7 days to 26.7 days
Cons
- Promoter holding has decreased over last quarter: -15.2%
- Company has a low return on equity of 7.01% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 286 | 318 | 437 | 566 | 756 | |
| 248 | 302 | 389 | 465 | 589 | |
| Operating Profit | 37 | 16 | 49 | 101 | 167 |
| OPM % | 13% | 5% | 11% | 18% | 22% |
| 5 | 10 | 6 | 8 | 14 | |
| Interest | 7 | 10 | 16 | 20 | 21 |
| Depreciation | 34 | 42 | 47 | 56 | 72 |
| Profit before tax | 1 | -27 | -9 | 33 | 87 |
| Tax % | 31% | -21% | 37% | -6% | 23% |
| 1 | -21 | -12 | 35 | 67 | |
| EPS in Rs | 3.40 | -106.93 | -58.69 | 169.82 | 321.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 34% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 72% |
| TTM: | 89% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 7% |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 4 |
| Reserves | 245 | 391 | 384 | 409 | 579 | 713 |
| 140 | 119 | 200 | 271 | 261 | 261 | |
| 42 | 59 | 81 | 124 | 153 | 215 | |
| Total Liabilities | 428 | 571 | 666 | 806 | 994 | 1,194 |
| 192 | 205 | 239 | 356 | 396 | 475 | |
| CWIP | 2 | 43 | 34 | 1 | 6 | 11 |
| Investments | 0 | 0 | 0 | 0 | 51 | 123 |
| 234 | 322 | 393 | 449 | 542 | 585 | |
| Total Assets | 428 | 571 | 666 | 806 | 994 | 1,194 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 32 | 14 | 11 | 72 | 135 | |
| -62 | -130 | -76 | -52 | -125 | |
| 36 | 121 | 60 | 27 | 54 | |
| Net Cash Flow | 5 | 6 | -4 | 47 | 65 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 101 | 123 | 132 | 131 | 129 |
| Inventory Days | 65 | 50 | 67 | ||
| Days Payable | 56 | 70 | 63 | ||
| Cash Conversion Cycle | 110 | 103 | 137 | 131 | 129 |
| Working Capital Days | 26 | 55 | 19 | 56 | 27 |
| ROCE % | -4% | 1% | 8% | 14% |
Documents
Announcements
-
Issuance Of Corporate Guarantee For And On Behalf Of Nephrocare Health Care Services Philippines Inc. Philippines Step-Down Wholly-Owned Subsidiary Not Exceeding USD 6.00 Million.
15 Jan - Board approved corporate guarantee up to USD 6.0 million for Philippines step-down subsidiary (Jan 15, 2026).
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
15 Jan - Certificate under Reg 74(5) for quarter ended Dec 31, 2025 confirming demat/remat details furnished to exchanges.
-
We Would Like To Inform That Pursuant To The Listing Of Equity Shares Of The Company On The Recognized Stock Exchanges Namely BSE Limited And National Stock Exchange Of India Limited The CIN Of The Company Has Been Changed From U85100TG2009PLC066359 To L8
15 Jan - CIN changed to L85100TG2009PLC066359 from U85100TG2009PLC066359 following equity listing (Jan 15, 2026).
- Announcement under Regulation 30 (LODR)-Newspaper Publication 8 Jan
-
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
7 Jan - Postal ballot: re-appoint Om Prakash Manchanda Feb11,2026–Feb10,2029; secretarial auditor Apr1,2025–Mar31,2030 at ₹2,75,000; e-voting Jan8–Feb6,2026.
Business Profile[1]
Nephrocare Health Services Limited (NHSL) is India’s largest dialysis-care provider offering a full spectrum of renal-care services haemodialysis, peritoneal dialysis, home haemodialysis, dialysis-on-call, dialysis-on-wheels, pharmacy support, diagnostics, and wellness management. It operates through captive hospital-based clinics, standalone centres, and large Public-Private Partnership (PPP) units.